Research programme : bromodomain and extraterminal domain protein inhibitors - Checkpoint/Jubilant/TG TherapeuticsAlternative Names: BET inhibitors; BRD4 Inhibitors - Jubilant/Checkpoint; CK-103
Latest Information Update: 16 Sep 2016
At a glance
- Originator Jubilant Biosys
- Developer Checkpoint Therapeutics; Jubilant Biosys; TG Therapeutics Inc
- Class Small molecules
- Mechanism of Action BRD4-protein-inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer